Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8603270 | 0.85 | ADRA2A (0.46) | DPP4F2TAAR1ADRA2AADRA2C | |
| SCHEMBL20271341 | 0.85 | DPP4 (0.46) | DPP4F2HTR2ATAAR1SCN4A | |
| SCHEMBL8131172 | 0.85 | ADRA2A (0.46) | DPP4F2TAAR1ADRA2AADRA2C | |
| Ether SCHEMBL28580867 | 0.84 | DPP4 (0.41) | DPP4F2HTR2ATAAR1SCN4A | |
| SCHEMBL2188803 | 0.78 | DPP4 (0.50) | DPP4F2HTR2ATAAR1SCN4A | |
| SCHEMBL10289765 | 0.78 | DPP4 (0.50) | DPP4F2HTR2ATAAR1SCN4A | |
| SCHEMBL114840 | 0.78 | DPP4 (0.50) | DPP4F2HTR2ATAAR1SCN4A | |
| Hydrochloric Acid SCHEMBL27904369 | 0.76 | DPP4 (0.48) | DPP4F2TAAR1ADRA2AADRA2C | |
| SCHEMBL1152103 | 0.76 | SCN4A (0.48) | DPP4F2HTR2ATAAR1SCN4A | |
| Hydrochloric Acid SCHEMBL28458580 | 0.74 | SCN4A (0.47) | DPP4F2SCN4ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MED LTD (GB) | 2026-05-07 | — | — | US | claimed |
| EP-4598592-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | Owlstone Medical Limited (GB) | 2025-08-13 | — | — | EP | claimed |
| CN-120152745-A | Compounds and their use for detecting diseases in exhaled breath of a subject | 奥斯通医疗有限公司 | 2025-06-13 | — | — | CN | claimed |
| WO-2024074813-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MEDICAL LIMITED (GB) | 2024-04-11 | — | — | WO | claimed |
| CN-108997147-B | Synthesis and use of N-alkyl amino benzene alkyl ether | 深圳市广昌达石油添加剂有限公司 | 2020-12-22 | — | — | CN | claimed |
| EP-3166645-A1 | SITE SELECTIVE CONJUGATION OF AN OLIGONUCLEOTIDE CONJUGATE OR A SMALL MOLECULE TO A METAL BINDING PROTEIN | Affycon ApS (DK) | 2017-05-17 | — | — | EP | claimed |
| WO-2016005474-A1 | SITE SELECTIVE CONJUGATION OF AN OLIGONUCLEOTIDE CONJUGATE OR A SMALL MOLECULE TO A METAL BINDING PROTEIN | AFFYCON APS (DK) | 2016-01-14 | — | — | WO | claimed |
| US-7553816-B2 | p-amidobenzylethers in drug delivery agents | SEATTLE GENETICS, INC. (US) | 2009-06-30 | — | — | US | claimed |
| US-7091186-B2 | p-Amidobenzylethers in drug delivery agents | SEATTLE GENETICS, INC. (US) | 2006-08-15 | — | — | US | claimed |
| US-20030130189-A1 | P-amidobenzylethers in drug delivery agents | SEAGEN INC. | 2003-07-10 | — | — | US | claimed |
| US-20030096743-A1 | p-Amidobenzylethers in drug delivery agents | SEATTLE GENETICS, INC. | 2003-05-22 | — | — | US | claimed |
| WO-2003026577-A2 | P-AMIDOBENZYLETHERS IN DRUG DELIVERY AGENTS | SEATTLE GENETICS, INC. (US) | 2003-04-03 | — | — | WO | claimed |
| US-20260139073-A1 | Antigen Binding Proteins | GLAXO GROUP LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MED LTD (GB) | 2026-05-07 | — | — | US | disclosed |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-12466893-B2 | Antigen binding proteins | GLAXO GROUP LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| EP-1233970-A2 | PROTECTING GROUPS USEFUL IN THE SYNTHESIS OF POLYSACCHARIDES, NATURAL PRODUCTS, AND COMBINATORIAL LIBRARIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6426421-B1 | HALOGENATED BENZYL ETHER-BASED PROTECTING GROUPS FOR FUNCTIONAL GROUPS, OF ALCOHOLS, THIOLS, AMINES, CARBOXYLIC ACIDS, AND PHOSPHORIC ACIDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2002-07-30 | — | — | US | disclosed |
| WO-2001038337-A2 | PROTECTING GROUPS USEFUL IN THE SYNTHESIS OF POLYSACCHARIDES, NATURAL PRODUCTS, AND COMBINATORIAL LIBRARIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-05-31 | — | — | WO | disclosed |
| US-4156618-A | REACTING ALDOSES WITH AN AMINE CONTAINING POLYMER | ASAHI-DOW LIMITED (JP) | 1979-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130189-A1 | P-amidobenzylethers in drug delivery agents | ZYX, LPXN, NPBWR1 | DPP4 325/4885F2 754/4885HTR2A 3410/4885 |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | BRCA1, L3MBTL1, LMNA | DPP4 2565/4885F2 254/4885HTR2A 4129/4885 |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | DPP4 2867/4885F2 4882/4885HTR2A 4802/4885 |
| US-12466893-B2 | Antigen binding proteins | CD40, TNFSF11, CD40LG | DPP4 2859/4885F2 3110/4885HTR2A 3859/4885 |
| US-20260139073-A1 | Antigen Binding Proteins | TNFSF11, TNFSF10, CD40 | DPP4 4056/4885F2 1108/4885HTR2A 4080/4885 |
| US-20030096743-A1 | p-Amidobenzylethers in drug delivery agents | ZYX, LPXN, NPBWR1 | DPP4 330/4885F2 713/4885HTR2A 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.